Video Editing for Biotech Companies Explaining Science to People Who Fund It

Biotech companies have a communication challenge that is honestly unlike almost any other industry, right, because the work is extraordinarily complex, it takes years or decades to pay off, and yet the company has to explain it clearly to investors deciding whether to fund it, partners deciding whether to license it, scientists deciding whether to join and sometimes patient communities hoping it will help them one day.

And on top of that, what a biotech company can say publicly is often constrained, basically by securities rules if it is listed or raising money, by regulators if it talks about therapies in development, and by the need to protect intellectual property, so a lot of biotech companies end up saying very little, or publishing dense scientific material that almost nobody outside the field can follow.

Why does biotech need clear video?

Because the audiences that decide a biotech company's future are rarely specialists in its exact science.

For instance, a generalist investor, a business development lead at a larger pharma company, a talented scientist from a neighbouring field or a patient advocacy group all need to understand what the company does and why it matters, without a PhD in that specific area. Clear video explanations bridge that gap in a way papers and decks cannot.

The catch here is accuracy, because simplifying science is essential and oversimplifying it into claims the data does not support is dangerous, both legally and for credibility.

Biotech is funded, partnered and staffed by people who are not experts in your exact science. Clear explanation is not marketing fluff, it is survival.

What should a biotech company publish?

Science explainers, scientist perspectives, conference content and recruitment content.

That is one category, science explainers, what the company's platform or approach does, explained accurately in plain language with good visuals. Secondly, scientist perspectives, researchers explaining their field, recent developments and why the problem matters. And on top of that, conference content, presentations and posters recorded and clipped, which extends the reach of scientific meetings far beyond the room.

Recruitment content is often the most valuable of all, because biotech companies compete fiercely for scarce scientific talent.

What are the legal limits on biotech communication?

Significant, especially for listed companies and anything touching therapies in development.

Publicly listed companies usually face rules about disclosing material information fairly and consistently, and forward looking statements often need appropriate caveats. Companies raising money privately may face restrictions on public solicitation. And content about investigational therapies must not suggest they are safe or effective before regulators have approved them.

For the edit, right, that means content should be reviewed by legal, regulatory and investor relations teams before publication, claims must match published data, and nothing should promote an unapproved therapy to patients. Those teams are the authority here, and a good editing partner builds their review into the workflow.

How should biotech companies handle patient communities?

With great care, respect and no promotion of unapproved treatments.

Patient communities are often deeply engaged with research that might one day help them. Biotech companies can share general information about the disease area and the science, and they can support awareness, but they must not promote investigational products or create false hope. Clinical trial information, where shared, should follow regulatory requirements and point people to official trial registries and their doctors.

What should a biotech company record?

Scientist interviews, conference presentations, lab footage and leadership updates.

A regular session where scientists explain their work in plain language produces explainers and short clips. Conference presentations, recorded with permission, provide substantial material. Lab footage, filmed with attention to confidentiality and safety, shows the work being done. Leadership updates, reviewed by the right teams, keep investors and partners informed.

Does that make sense, right, most of this content already exists as talks and conversations, it just needs capturing and editing carefully.

Whose faces should be in the videos?

Scientists first, then leadership.

Investors, partners and potential hires want to see the people doing the science. Scientists explaining their work with enthusiasm and clarity are the most credible voices a biotech company has. Leadership matters for strategy and milestones, but a company whose content only features executives can feel distant from its science.

Which platforms matter for biotech companies?

LinkedIn above all, then YouTube and the company website.

LinkedIn is where investors, partners, scientists and industry professionals spend professional attention, and LinkedIn's help centre covers native video. YouTube hosts longer explainers and conference talks. The company website should embed explainers for investors and partners researching the company.

What should a biotech company budget for video editing?

Small, relative to the value of successful fundraising, partnering and hiring.

An early stage biotech publishing occasional explainers is well served by a freelance editor paid per video. Larger companies with regular conference content, investor communications and active recruitment need more capacity, and our published entry price is two thousand dollars a month, covering up to thirty long form videos and two hundred short form clips, thumbnails included, edited by close to fifty in-house editors in Dubai, while deeper strategy work costs more. The comparisons pages explain the pricing models.

What mistakes do biotech companies make with video?

Jargon, silence and claims that outrun the evidence.

That is one, content only specialists can follow. Secondly, going silent between milestones, which leaves investors and partners with nothing. Then the third thing, enthusiastic claims that go beyond the data, which create legal risk and damage credibility with sophisticated audiences.

How long before video makes a difference?

Recruitment effects can appear within months, while investor and partner effects build over longer cycles.

Signs of success include candidates mentioning the company's content, partners referencing explainers in early conversations and investors arriving better informed.

How should biotech companies use animation?

As a tool for showing mechanisms that cannot be filmed, right, while staying faithful to the science.

Much of what biotech companies do happens at molecular or cellular scale, which cameras cannot capture. Clear animation showing how a therapy targets a cell, how a platform works or how a mechanism operates can make complex science understandable to non specialists. The catch here is accuracy, because animation that oversimplifies or dramatises effects can mislead, so scientists should review every frame for scientific fidelity.

What about partnering and business development?

Video can shorten the path to a first conversation with potential partners.

Business development teams at larger companies scan many opportunities. A clear, short explainer of a platform's capabilities, the data behind it and the team's expertise, shared ahead of a conference or a meeting, helps a partner quickly understand whether the fit is worth exploring. It needs the same legal and confidentiality review as any other external content.

How do you protect intellectual property in lab footage?

By planning shots carefully and reviewing every frame before publishing.

Lab footage can accidentally reveal confidential information, a whiteboard with unpublished data, a screen showing results, a label on a sample, a piece of proprietary equipment. Filming should be planned with the scientific team, sensitive areas avoided, and footage reviewed frame by frame by someone who knows what is confidential, does that make sense to you, right, a single visible whiteboard can be a real problem.

How should biotech companies communicate setbacks?

Carefully, promptly and consistently with their disclosure obligations.

Trials fail, programmes are paused and timelines slip, and how a company communicates those moments affects its credibility with investors, partners and employees. For listed companies, disclosure rules govern timing and content. Where video is used, it should be reviewed by legal and investor relations and should acknowledge the setback honestly rather than spinning it.

How often should a biotech company publish?

Steadily, with a rhythm tied to scientific and corporate milestones.

A regular cadence of scientist explainers and recruitment content, supplemented by conference coverage and approved milestone updates, keeps the company visible between major announcements. Batching content for review makes regular publishing practical within the necessary approvals.

Can video help a biotech company build its employer brand?

Very much, because the best scientists choose where to work partly on the people and the mission.

Scientists weighing offers want to know who they would work with, how the lab operates, what resources they would have and how their work would be recognised. Short videos of team members explaining their research and what they enjoy about the company give candidates exactly that, and they are far more persuasive than a careers page. In a field where hiring a single key scientist can change a programme's trajectory, that matters.

Should biotech leaders build a personal presence?

Often, right, because investors and partners back people as much as platforms.

A chief executive or chief scientific officer who explains the company's science and strategy clearly on LinkedIn, within disclosure rules, becomes a recognisable voice in the field. That visibility helps with fundraising, partnering and hiring, and it gives the company a human face in an industry that can feel abstract to outsiders.

Where should a biotech company start?

With your best communicating scientist explaining your platform in five plain language minutes, reviewed by legal first.

The piece on video for medtech companies covers regulated health communication, and turning conference talks into a year of content covers event footage. The B2B companies page has more on how we work with technical businesses. So yeah. That's my way of saying it.